



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Present at Two Upcoming June Conferences

June 1, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2018-- [Seres Therapeutics, Inc.](http://www.serestherapeutics.com) (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences:

- **Jefferies 2018 Global Healthcare Conference:** a corporate overview will be presented on Wednesday, June 6 at 4:30 p.m. ET in New York, NY.
- **Goldman Sachs 39<sup>th</sup> Annual Global Healthcare Conference:** a corporate overview will be presented on Wednesday, June 13 at 9:20 a.m. PT in Palos Verdes, CA.

A live audio webcast of each presentation will be available under the "Investors and Media" section of Seres' website. A replay of each presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent *C. difficile* infection. Seres' clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter [@SeresTx](https://twitter.com/SeresTx).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180601005213/en/>

Source: Seres Therapeutics, Inc.

### IR or PR:

Seres Therapeutics  
Carlo Tanzi, Ph.D., 617-203-3467  
Vice President, Investor Relations and Corporate Communications  
[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)